Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease

[1]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[2]  R. L. Baldwin,et al.  Formation of ion-permeable channels by tumor necrosis factor-alpha. , 1992, Science.

[3]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[4]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[5]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[6]  A. Imperato,et al.  Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice , 1997, Neuroscience Letters.

[7]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[8]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[9]  A. Członkowska,et al.  The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse , 1999, Experimental Neurology.

[10]  H. Ichinose,et al.  Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction , 1999, Neuroscience Letters.

[11]  R. Krüger,et al.  Genetic analysis of immunomodulating factors in sporadic Parkinson's disease , 2000, Journal of Neural Transmission.

[12]  S. Gupta.  Molecular steps of tumor necrosis factor receptor-mediated apoptosis. , 2001, Current molecular medicine.

[13]  E. Benveniste,et al.  Immune function of astrocytes , 2001, Glia.

[14]  S. Klahr,et al.  Contributions of angiotensin II and tumor necrosis factor-α to the development of renal fibrosis , 2001 .

[15]  B. Ferger,et al.  Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease , 2001, Synapse.

[16]  R. Kaji,et al.  Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease , 2001, Neuroscience Letters.

[17]  D. Miller,et al.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Rena Li,et al.  Target Depletion of Distinct Tumor Necrosis Factor Receptor Subtypes Reveals Hippocampal Neuron Death and Survival through Different Signal Transduction Pathways , 2002, The Journal of Neuroscience.

[19]  Andreas Hartmann,et al.  Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP , 2002, Experimental Neurology.

[20]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[21]  Sudhir Gupta,et al.  A Decision Between Life and Death During TNF-α-Induced Signaling , 2002, Journal of Clinical Immunology.

[22]  J. Feldon,et al.  Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum , 2004, Journal of neurochemistry.